STK11 and non-small cell lung carcinoma: and Scalera et al., pointing out that molecular stratification of both alterations should be implemented for localized and advanced-stage NSCLC to optimize and modify clinical decision-making (29, 30), even though both studies did not include KRAS and/or STK11 in their investigations.